首页 > 用药指导 > 文章详情

Baricitinib(巴瑞替尼)艾乐明的适用人群

发布时间:2025-05-01 08:47:00 阅读:1239 来源:问药网
分享至

分享到微信朋友圈

×
Scan me!

打开微信,点击底部的“发现”,

使用“扫一扫”即可将网页分享至朋友圈。

巴瑞替尼片

巴瑞替尼片 生产厂家:孟加拉DIL耀品国际制药公司 功能主治:对一种或多种抗风湿药物缓解不足或不耐受的中度至重 用法用量:用法用量  1、类风湿性关节炎  OLUMIANT的推荐剂量为每日1次口服2mg,餐前餐后都可。  OLUMIANT可以单独使用,也可以与甲氨蝶呤或其他非生物dmard联合使用。  2、COVID-19(新冠病毒)  成人OLUMIANT的推荐剂量为每日一次口服4mg,餐前餐后都可,持续14天或直到出院,以先发生者为准。  3、斑秃  OLUMIANT的推荐剂量是2mg,每天一次口服,餐前餐后都可。  如果对治疗的反应不充分,增加到每天一次4mg。  对于几乎完全或完全的头皮脱发,睫毛或眉毛有或没有大量脱发的患者,考虑每天一次4mg治疗,伴餐前餐后都可。  一旦患者对4mg的治疗产生了充分的反应,将剂量减少到2mg,每天一次。  对于无法吞下整片药片的患者,可以考虑另一种给药方式:  1、口服分散  2、胃造口管(G管)  3、鼻胃管(NG管)或口胃管(OG管)
查看详情

Baricitinib(巴瑞替尼)艾乐明的适用人群,巴瑞替尼(Baricitinib)适用于:1、类风湿性关节炎患者;2、斑秃患者;3、新冠肺炎患者;4、系统性红斑狼疮患者。

Baricitinib (trade name: Olumiant) is a medication that has shown effectiveness in treating various conditions, including rheumatoid arthritis, COVID-19, and alopecia areata. In this article, we will discuss the target population suitable for the use of Baricitinib. It is important to note that the use of any medication should always be guided by a healthcare professional, and this article is for informational purposes only.

1. Baricitinib for Rheumatoid Arthritis:

Rheumatoid arthritis is a chronic autoimmune disease that primarily affects the joints, causing inflammation, pain, and stiffness. Baricitinib has been approved for the treatment of moderate to severe rheumatoid arthritis in adults who have not responded well to other disease-modifying antirheumatic drugs (DMARDs). It is particularly suitable for individuals who require additional therapy to control their symptoms and improve their overall quality of life.

2. Baricitinib for COVID-19:

In response to the global COVID-19 pandemic, Baricitinib has been investigated as a potential treatment for patients with severe symptoms. It is believed to be effective due to its ability to modulate the immune response associated with the progression of the disease. Baricitinib, in combination with remdesivir, has been granted an emergency use authorization by several regulatory authorities for the treatment of COVID-19 in hospitalized patients who require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

3. Baricitinib for Alopecia Areata:

Alopecia areata is an autoimmune condition that causes hair loss on the scalp and other areas of the body. Baricitinib has shown promise as a potential therapy for this condition. By targeting and modulating the immune response, Baricitinib may help stimulate hair regrowth in individuals with alopecia areata. However, the use of Baricitinib for alopecia areata is still at the investigational stage, and further research is needed to establish its safety and efficacy.

In conclusion, Baricitinib, under the trade name Olumiant, is a medication that has demonstrated efficacy in the treatment of rheumatoid arthritis, COVID-19, and potentially alopecia areata. However, it is crucial to consult with a healthcare professional before considering the use of Baricitinib, as they can provide personalized advice and assess whether it is suitable for your individual circumstances. Always follow the prescribed dosage and adhere to any additional recommendations provided by your healthcare provider to ensure the safe and effective use of Baricitinib.